

THE LANCET

Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. *Lancet* 2010; published online March 24. DOI:10.1016/S0140-6736(10)60059-1.

Web Appendix

Page 1

Recent meta-analyses of surgery ($\pm$ radiotherapy) + chemotherapy versus surgery ($\pm$ radiotherapy)

Author	Year	Type of Data	Number of trials	Number of patients	Hazard ratio (95%CI)
Hotta et al ¹	2004	Published data	11*	5716	0.87 (0.81-0.94)
Sedrakyan et al ²	2004	Published data	19	7200	0.87 (0.81-0.93)
Berghmans et al ³	2005	Published data	17	7644	0.85 (0.79-0.91)
Bria et al ⁴	2005	Published data	11 + 1 meta-analysis	6494	0.93 (0.89-0.95)
Hamada et al ⁵	2005	Individual patient data	6**	2003	0.74 (0.61-0.88)
Pignon et al (LACE) ⁶	2006	Individual patient data	5†	4584	0.89 (0.82-0.96)

* Recent trials only

** UFT trials only

† Large (>300 patients) and recent cisplatin trials only

Web Appendix

Page 2

Patient characteristics for trials of surgery + chemotherapy versus surgery and for trials of surgery + radiotherapy + adjuvant chemotherapy versus surgery + radiotherapy


Characteristic	Surgery + Chemotherapy (n=4305)	Surgery (n=4142)	Surgery + Radiotherapy + Chemotherapy (n=1315)	Surgery + Radiotherapy (n=1345)
Age (years)				
<60	1827 (46%)	1669 (44%)	692 (53%)	693 (51%)
60-64	898 (17%)	900 (18%)	270 (20%)	292 (22%)
65-69	872 (20%)	878 (21%)	253 (19%)	253 (19%)
>=70	593 (14%)	583 (14%)	100 (8%)	107 (8%)
Unknown	115 (3%)	112 (3%)		
Sex				
Male	2948 (68%)	2876 (69%)	1023 (78%)	1062 (79%)
Female	1238 (29%)	1149 (28%)	291 (22%)	281 (21%)
Unknown	119 (3%)	117 (3%)	1 (<1%)	2 (<1%)
Histology				
Adenocarcinoma	2257 (52%)	2158 (52%)	499 (38%)	501 (37%)
Squamous	1649 (38%)	1587 (38%)	642 (49%)	655 (49%)
Other	386 (9%)	391 (9%)	172 (13%)	184 (14%)
Unknown	13 (<1%)	6 (<1%)	2 (<1%)	5 (<1%)
Stage				
I	2851 (66%)	2772 (67%)	20 (2%)	14 (1%)
II	806 (19%)	793 (19%)	450 (34%)	473 (35%)
IIIA	586 (14%)	512 (12%)	804 (61%)	801 (60%)
IIIB	31 (<1%)	42 (1%)	21 (2%)	30 (2%)
Stage III Unspecified	n/a	n/a	n/a	3 (<1%)
IV	13 (<1%)	10 (<1%)	3 (<1%)	0 (0%)
Unknown	18 (<1%)	13 (<1%)	17 (1%)	24 (2%)
Performance status*				
Good	3172 (74%)	3022 (73%)	948 (72%)	969 (72%)
Poor	96 (2%)	83 (2%)	81 (6%)	105 (8%)
Unknown	76 (2%)	58 (1%)	22 (2%)	16 (1%)
Not supplied	961 (22%)	979 (24%)	264 (20%)	255 (19%)
Extent of resection				
Complete	4119 (96%)	3951 (95%)	1097 (83%)	1121 (83%)
Incomplete	120 (3%)	123 (3%)	179 (14%)	186 (14%)
Unknown	66 (1%)	68 (2%)	39 (3%)	38 (3%)
Radiotherapy timing				
Chemotherapy before radiotherapy	n/a	n/a	941 (72%)	963 (72%)
Concomitant chemotherapy and radiotherapy	n/a	n/a	374 (28%)	382 (28%)

*Good=0,1 ECOG/OMS or 100-70 Karnofsky; Poor≥2 ECOG/OMS or ≤60 Karnofsky

Web Appendix

Page 3


Exploratory analyses of the effect of surgery (S) and chemotherapy (CT) versus surgery on survival, by the use of UFT/tegafur



Web Appendix

Page 4

The effect of surgery (S) and chemotherapy (CT) versus surgery on survival, by patient subgroup
Only patients that were included in the estimation of the subgroup HRs are included in the subgroup totals




Web Appendix

Page 5

The effect of surgery and radiotherapy and chemotherapy versus surgery and radiotherapy on survival by patient subgroup

Only patients that were included in the estimation of the subgroup HRs are included in the subgroup totals



Web Appendix

Page 6

References

1. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: Reappraisal with a meta-analysis of randomised controlled trials. *Journal of Clinical Oncology* 2004; 22:3860-7.
2. Sedrakyan A, van Der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. *Journal of Thoracic and Cardiovascular Surgery* 2004; 128:414-9.
3. Berghmans T, Paesmans M, Meert AP *et al.* Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. *Lung Cancer* 2005; 49:13-23.
4. Bria E, Gralla RJ, Raftopoulos H *et al.* Does adjuvant chemotherapy improve survival in non-small cell lung cancer (NSCLC)? A pooled analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit. *Journal of Clinical Oncology* 2005; 23(16S):7140.
5. Hamada C, Tanaka F, Ohta M *et al.* Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small cell lung cancer. *Journal of Clinical Oncology* 2005; 23(22):4999-5006.
6. Pignon JP, Tribodet H, Scagliotti GV *et al.* Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE Collaborative Group. *Journal of Clinical Oncology* 2008; 26(21):3552-9.